monoclonal antibodies

knight with sword and shield
October 20, 2016

Research sheds light on how RSV wards off potential vaccines

Respiratory syncytial virus (RSV) is the major cause of life-threatening viral pneumonia in infants worldwide, yet despite repeated efforts, scientists have been unable to develop an effective vaccine against it.

By Bill Snyder
drawing of trojan horse
September 8, 2016

Investigators create ‘Trojan Horse’ to fight Ebola

A multi-center research team including scientists from the Vanderbilt Vaccine Center has come up with a clever “Trojan Horse” strategy for thwarting the highly lethal Ebola virus.

By Bill Snyder
goofy toy disguise
August 11, 2016

Research team takes aim at Ebola virus ‘decoy protein’

Using an antibody generated at Vanderbilt University Medical Center that neutralizes the Ebola virus, researchers at the Scripps Research Institute in La Jolla, California, have determined the structure of a “decoy” protein that may enable the virus to evade detection by the immune system.

By Bill Snyder
March 7, 2016

Vanderbilt researchers identify potential antibody treatment for H7 avian flu

Researchers at Vanderbilt University Medical Center have isolated human antibodies against a type of bird flu that has killed more than 200 people in China since 2012 and which may pose a worldwide pandemic threat.

By Bill Snyder
January 21, 2016

Antibodies may be ‘silver bullet’ for Ebola viruses

There may be a “silver bullet” for Ebola, a family of hemorrhagic viruses, one of which has killed more than 11,000 people in West Africa in the past two years.

By Bill Snyder
July 9, 2015

Study could lead to vaccine for mosquito-borne dengue virus

Researchers at Vanderbilt University and the National University of Singapore have determined the structure of a human monoclonal antibody which, in an animal model, strongly neutralizes a type of the potentially lethal dengue virus.

By Bill Snyder
April 8, 2015

VU joins national effort to speed Ebola therapy testing

Vanderbilt University researchers have joined a multi-center effort led by Pennsylvania-based Inovio Pharmaceuticals Inc. to accelerate development of potential antibody therapies against the often-lethal Ebola virus.
By Bill Snyder
January 29, 2015

Core facilities key driver of VUMC research gains

During the past five years, Vanderbilt University Medical Center has become a leader in “personalized medicine,” the use of genomic information to individualize patient care.
By Bill Snyder
November 13, 2014

Speaker explores promise of ‘bioelectronic medicine’

Can an implanted electrical device like a cardiac pacemaker effectively treat inflammatory diseases like rheumatoid arthritis, including cases that have not responded to drug therapy?
By Bill Snyder
September 24, 2014

Alexander’s visit highlights efforts to confront Ebola

Don’t panic over Ebola. But don’t ignore it, either. That was the take-home message for U.S. citizens from a “mini-hearing” held by U.S. Sen. Lamar Alexander, R-Tenn., at Vanderbilt University Medical Center on Wednesday with researchers and health officials from Vanderbilt and the State of Tennessee.
By Bill Snyder
September 18, 2014

Initiative seeks to develop therapies to combat Ebola

Vanderbilt University researchers have partnered with Mapp Biopharmaceutical Inc. to develop new human antibody therapies for people exposed to the deadly Ebola and Marburg viruses.
By Bill Snyder
March 6, 2014

Multi-center effort targets lethal Ebola, Marburg viruses

Vanderbilt University researchers are collaborating in a multi-center, federally-funded project to develop ways to treat and prevent the highly lethal Ebola and Marburg virus infections.
By Bill Snyder
May 16, 2013

Grant targets new therapies for Ebola, Marburg viruses

Vanderbilt’s James Crowe Jr., M.D., and a collaborator in Texas have been awarded a $4.4 million grant from the U.S. Department of Defense to study new ways to treat and prevent Ebola and Marburg viruses.
By VUMC News and Communications